Jump to content

About This Club

Tandem Diabetes Care is a public US medical device manufacturer based in San Diego, CA. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.

Location

San Diego, California

  1. What's new in this club
  2. Investors would have done much better keeping an eye on Tandem Diabetes Care, a small, promising -- yet still risky -- medical products company that is growing sales, but also losing money. In the first quarter, it sold a few thousand of its next-generation insulin pump, the t:slim X2, and says it needs an installed base of 80,000 pumps to break even on a cash flow basis, though it believes it can hit that milestone some time next year. Because diabetes is a huge growth market, with the incidence of the disease expected to grow 165% in the U.S. by 2050, Tandem has a promising technology that analysts believe, if successful, could challenge Medtronic (NYSE:MDT) for industry leadership. Medtronic offers a competing technology called a continuous glucose monitor (CGM) that tracks a patient's blood sugar over time to let them better manage their disease. As diabetics seek alternatives to insulin injections to regulate their condition, Tandem has partnered with DexCom to bring its insulin pump system (that works with DexCom's monitoring system) to market early next year. The artificial pancreas monitors patients' blood glucose levels and uses an algorithm to know when to deliver an appropriate dose of insulin. At least one analyst thinks highly of Tandem's prospects for being able to grab market share when its system is commercialized. He upgraded the stock, which sent shares soaring. Although Medtronic is many times larger than Tandem, its CGM device is also much larger than Tandem's t:slim X2, and thus more cumbersome. And DexCom's monitors, which work with both systems, can be used for longer periods of time with Tandem's pump, making them more convenient. Also, the need for finger pricks for dosing decisions isn't needed with the t:slim X2 whereas they're still necessary with Medtronic's MiniMed system. While the potential for Tandem Diabetes Care may be more promising than for NII Holdings, it also is a risky proposition. Even though the FDA just approved Tandem's pump with its newest technology that predicts where insulin level needs and adjusts production accordingly, Medtronic also received regulatory approval for its own enhanced CGM system that now allows for treating patients between ages seven and 13. It removes a competitive advantage Tandem had with its pump being able to be used on those as young as six. Tandem's finances are probably not going to look pretty either for awhile yet. Still, by the t:slim X2 getting approved for use with DexCom's more feature-rich monitoring technology, a development that wasn't expected, there's good reason why Tandem Diabetes Care shares are soaring.
  3. The Global Diabetes Care Devices Market is expected to exceed more than US$ 30.25 Billion by 2022 at a CAGR of 5.9% in the given forecast period Browse Full Report:
      Hello guest!
    The Global Diabetes Care Devices Market is segmented on the lines of its glucose monitoring devices, insulin delivery device, type and regional. Based on glucose monitoring device segmentation it covers blood glucose meters, blood glucose test strips, lancing devices, continuous glucose monitoring devices, HbA1c testing kits. Based on insulin delivery device segmentation it covers insulin pumps, insulin syringes and insulin pens. Based on type segmentation it covers therapy type, inject able, oral drugs. The major driving factors of Global Diabetes Care Devices Market are as follows: Increasing prevalence of diabetes care patients Development of technologies for diabetes Rising minimum or non-invasive products Growing awareness of diabetes care devices Development need for faster, safer and effective method of diagnosis and treatment of diabetes The restraining factors of Global Diabetes Care Devices Market are as follows: Expensive related with diagnosis and treatment Compensation issues and patent expiry This report provides: 1) An overview of the global market for Global Diabetes Care Devices Market and related technologies. 2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2022. 3) Identifications of new market opportunities and targeted promotional plans for Global Diabetes Care Devices Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry. The Global Diabetes Care Devices Market has been segmented as below: By Glucose Monitoring Devices Analysis: Blood Glucose Meters Blood Glucose Test Strips Lancing Devices Continuous Glucose Monitoring Devices HbA1c Testing Kits By Insulin Delivery Devices Analysis: Insulin Pumps Insulin Syringes Insulin Pens By Type Analysis: Therapy Type Injectable Oral Drugs By Regional Analysis: North America Europe Asia-Pacific Rest of the World Reasons to Buy this Report: 1) Obtain the most up to date information available on all Global Diabetes Care Devices Market. 2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast of Global Diabetes Care Devices Market data. 4) Assess your competitor's refining portfolio and its evolution.
  4. In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump.[7] In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump and supported blood glucose meters on a cloud-based platform. In January 2015, Tandem announced FDA clearance of the t:flex Insulin Pump, the largest capacity insulin pump on the market. In July 2014, Tandem announced that it had submitted a PMA for the t:slim G4, which integrates t:slim Pump technology with the Dexcom G4 Platinum CGM System. This device was approved by the FDA in September 2015.The FDA approved a tool to update the software on Tandem's pumps in July, 2016. The Tandem Product Updater is designed to deliver software updates to Tandem's pumps to provide new features and interface improvements. In announcing the approval, Tandem stated that the first use of the new tool will be to update t:slim pumps which were shipped prior to April, 2015 with a new version of the firmware which speeds the loading process and offers other enhancements. In late October 2016, Tandem began shipping its next-generation pump platform, the t:slim X2. The X2 will receive updates via the Tandem Product Updater product, with planned updates initially including integration with Dexcom's G5 and G6 Continuous Glucose Monitors, and eventually the integration of closed-loop technology which Tandem licensed from TypeZero in July 2016
  5. In 2006, a group of engineers recognized the need for new and improved methods of pumping insulin and incorporated as Phluid, Inc. In 2007, Kim Blickenstaff joined the organization as President and CEO, bringing his philosophy of using market research as the inspiration for product development and started on the development of the t:slim Insulin Pump. In 2008, this predecessor company became the newly incorporated Tandem Diabetes Care, Inc. that was formed with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. Tandem Diabetes Care felt that incorporating enhanced ease of use and attractive design—often associated with consumer electronics development—would also encourage more patients to consider the clinical benefits of insulin pump therapy. Tandem Diabetes Care interviewed more than 4,000 insulin pump users and health care providers to design its first device, the t:slim Insulin Pump. In 2016, the company was ranked #39 on the Deloitte Fast 500 North America list
  6.  




×
×
  • Create New...

Important Information

Terms of Service Confirmation Terms of Use Privacy Policy Guidelines We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.